Wide-field imaging of fluorescent deoxy-glucose in ex vivo malignant and normal breast tissue

Biomedical Optics Express

Volumn 2, Issue 6, 2011, Pages 1514-1523

  Langsner, R J ^a   Middleton, L P ^b   Sun, J ^c   Meric Bernstam, F ^b,d   Hunt, K K ^b,e   Drezek, R A ^a   Yu, T K ^f  

^a Rice University   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c SUZHOU INSTITUTE OF BIOMEDICAL ENGINEERING AND TECHNOLOGY   (China)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f Houston Precision Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; FLUORESCENCE; GLUCOSE; TISSUE; TRANSPLANTATION (SURGICAL);

BREAST CANCER; BREAST TISSUES; CANCEROUS CELLS; EX-VIVO; FLUORESCENT SIGNALS; IN-SITU; MALIGNANT TISSUES; MULTISPECTRAL IMAGES; OPTICAL CONTRAST AGENT; PRELIMINARY DATA; SURGICAL RESECTION; WIDE FIELD IMAGING;

MEDICAL IMAGING;

EID: 84857847549     PISSN: None     EISSN: 21567085     Source Type: Journal    
DOI: 10.1364/BOE.2.001514     Document Type: Article

References (29)

1. N. Q. Mirza, G. Vlastos, F. Meric, T. A. Buchholz, N. Esnaola, S. E. Singletary, H. M. Kuerer, L. A. Newman, F. C. Ames, M. I. Ross, B. W. Feig, R. E. Pollock, M. McNeese, E. Strom, and K. K. Hunt, "Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy, " Ann. Surg. Oncol. 9(3), 256-265 (2002).
2. A. Luini, J. Rososchansky, G. Gatti, S. Zurrida, P. Caldarella, G. Viale, G. Rosali dos Santos, and A. Frasson, "The surgical margin status after breast-conserving surgery: discussion of an open issue, " Breast Cancer Res. Treat. 113(2), 397-402 (2009).
3. L. R. Bickford, G. Agollah, R. Drezek, and T. K. Yu, "Silica-gold nanoshells as potential intraoperative molecular probes for HER2-overexpression in ex vivo breast tissue using near-infrared reflectance confocal microscopy, " Breast Cancer Res. Treat. 120(3), 547-555 (2010).
4. L. P. Adler, P. F. Faulhaber, K. C. Schnur, N. L. Al-Kasi, and R. R. Shenk, "Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET, " Radiology 203(2), 323-327 (1997).
5. M. Schelling, N. Avril, J. Nährig, W. Kuhn, W. Römer, D. Sattler, M. Werner, J. Dose, F. Jänicke, H. Graeff, and M. Schwaiger, "Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer, " J. Clin. Oncol. 18(8), 1689-1695 (2000).
6. R. L. Wahl, R. L. Cody, G. D. Hutchins, and E. E. Mudgett, "Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose, " Radiology 179(3), 765-770 (1991).
7. O. Warburg, F. Wind, and E. Negelein, "The metabolism of tumors in the body, " J. Gen. Physiol. 8(6), 519-530 (1927).
8. L. P. Adler, J. P. Crowe, N. K. al-Kaisi, and J. L. Sunshine, "Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET, " Radiology 187(3), 743-750 (1993).
9. R. S. Brown, J. Y. Leung, P. V. Kison, K. R. Zasadny, A. Flint, and R. L. Wahl, "Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer, " J. Nucl. Med. 40(4), 556-565 (1999).
10. R. S. Brown and R. L. Wahl, "Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study, " Cancer 72(10), 2979-2985 (1993).
11. G. Weber and A. Cantero, "Glucose-6-phosphatase activity in normal, pre-cancerous, and neoplastic tissues, " Cancer Res. 15(2), 105-108 (1955).
12. K. Yu, S. J. Schomisch, V. Chandramouli, and Z. Lee, "Hexokinase and glucose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma, " Comp. Biochem. Physiol. Part Toxicol. Pharmacol. 143(2), 225-231 (2006).
13. K. Yamada, M. Nakata, N. Horimoto, M. Saito, H. Matsuoka, and N. Inagaki, "Measurement of glucose uptake and intracellular calcium concentration in single, living pancreatic beta-cells, " J. Biol. Chem. 275(29), 22278-22283 (2000).
14. R. G. O'Neil, L. Wu, and N. Mullani, "Uptake of a fluorescent deoxyglucose analog (2-NBDG) in tumor cells, " Mol. Imaging Biol. 7(6), 388-392 (2005).
15. N. Nitin, A. L. Carlson, T. Muldoon, A. K. El-Naggar, A. Gillenwater, and R. Richards-Kortum, "Molecular imaging of glucose uptake in oral neoplasia following topical application of fluorescently labeled deoxy-glucose, " Int. J. Cancer 124(11), 2634-2642 (2009).
16. A. Fourquet, F. Campana, B. Zafrani, V. Mosseri, P. Vielh, J. C. Durand, and J. R. Vilcoq, "Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up, " Int. J. Radiat. Oncol. Biol. Phys. 17(4), 719-725 (1989).
17. M. C. Smitt, K. Nowels, R. W. Carlson, and S. S. Jeffrey, "Predictors of reexcision findings and recurrence after breast conservation, " Int. J. Radiat. Oncol. Biol. Phys. 57(4), 979-985 (2003).
18. S. C. Renton, J. C. Gazet, H. T. Ford, C. Corbishley, and R. Sutcliffe, "The importance of the resection margin in conservative surgery for breast cancer, " Eur. J. Surg. Oncol. 22(1), 17-22 (1996).
19. C. A. Perez, "Conservation therapy in T1-T2 breast cancer: past, current issues, and future challenges and opportunities, " Cancer J. 9(6), 442-453 (2003).
20. M. E. Peterson, D. J. Schultz, C. Reynolds, and L. J. Solin, "Outcomes in breast cancer patients relative to margin status after treatment with breast-conserving surgery and radiation therapy: the University of Pennsylvania experience, " Int. J. Radiat. Oncol. Biol. Phys. 43(5), 1029-1035 (1999).
21. R. Heimann, C. Powers, H. J. Halpern, A. G. Michel, C. A. Ewing, B. Wyman, W. Recant, and R. R. Weichselbaum, "Breast preservation in stage I and II carcinoma of the breast. the University of Chicago experience, " Cancer 78(8), 1722-1730 (1996).
22. R. Bos, J. J. M. van Der Hoeven, E. van Der Wall, P. van Der Groep, P. J. van Diest, E. F. Comans, U. Joshi, G. L. Semenza, O. S. Hoekstra, A. A. Lammertsma, and C. F. Molthoff, "Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography, " J. Clin. Oncol. 20(2), 379-387 (2002).
23. N. Avril, M. Menzel, J. Dose, M. Schelling, W. Weber, F. Jänicke, W. Nathrath, and M. Schwaiger, "Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis, " J. Nucl. Med. 42(1), 9-16 (2001).
24. N. Y. Tse, C. K. Hoh, R. A. Hawkins, M. J. Zinner, M. Dahlbom, Y. Choi, J. Maddahi, F. C. Brunicardi, M. E. Phelps, and J. A. Glaspy, "The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease, " Ann. Surg. 216(1), 27-34 (1992).
25. R. Bos, J. J. M. van Der Hoeven, E. van Der Wall, P. van Der Groep, P. J. van Diest, E. F. Comans, U. Joshi, G. L. Semenza, O. S. Hoekstra, A. A. Lammertsma, and C. F. Molthoff, "Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography, " J. Clin. Oncol. 20(2), 379-387 (2002).
26. A. M. Byrne, A. D. K. Hill, S. J. Skehan, E. W. McDermott, and N. J. O'Higgins, "Positron emission tomography in the staging and management of breast cancer, " Br. J. Surg. 91(11), 1398-1409 (2004).
27. O. E. Nieweg, E. E. Kim, W. H. Wong, W. F. Broussard, S. E. Singletary, G. N. Hortobagyi, and R. S. Tilbury, "Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer, " Cancer 71(12), 3920-3925 (1993).
28. L. Arnould, M. Gelly, F. Penault-Llorca, L. Benoit, F. Bonnetain, C. Migeon, V. Cabaret, V. Fermeaux, P. Bertheau, J. Garnier, J. F. Jeannin, and B. Coudert, "Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?" Br. J. Cancer 94(2), 259-267 (2006).
29. S. F. Dent, S. Verma, K. I. Pritchard, J. Latreille, D. Rayson, M. Clemons, J. R. Mackey, L. Provencher, S. Verma, J. Lemieux, S. Chia, and B. Wang, "The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer, " Curr. Oncol. 16(4), 25-35 (2009).